NCT06312644View on ClinicalTrials.gov

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

RecruitingOBSERVATIONAL
Enrollment

75

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

July 11, 2034

Study Completion Date

July 11, 2034

Conditions
Ultomiris-exposed Pregnant/ PostpartumPregnancyParoxysmal Nocturnal Hemoglobinuria (PNH)Atypical Hemolytic Uremic Syndrome (aHUS)Generalized Myasthenia Gravis (gMG)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Interventions
DRUG

Ultomiris

Participants exposed to Ultomiris at any point during the 40 weeks prior to conception (LMP+14 days) or at any point during pregnancy or breastfeeding up to 52 weeks after birth.

Trial Locations (8)

3050

NOT_YET_RECRUITING

Research Site, Melbourne

75475

ACTIVE_NOT_RECRUITING

Research Site, Paris

02210

RECRUITING

Research Site, Boston

D-45147

RECRUITING

Research Site, Essen

00168

ACTIVE_NOT_RECRUITING

Research Site, Rome

Unknown

ACTIVE_NOT_RECRUITING

Research Site, Seoul

NOT_YET_RECRUITING

Research Site, Seoul

SE5 9NU

ACTIVE_NOT_RECRUITING

Research Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY